Literature DB >> 19096009

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.

Deepa Sampath1, George A Calin, Vinay K Puduvalli, Gopal Gopisetty, Cristian Taccioli, Chang-Gong Liu, Brett Ewald, Chaomei Liu, Michael J Keating, William Plunkett.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by cells that exhibit dysfunctional apoptosis. Here, we show that deacetylase inhibition led to the E2F1- and myc-mediated transcriptional activation of the microRNA miR106b in primary CLL cells. Induction of miR106b was associated with a down-regulation in the levels of the E3-ubiquitin ligase Itch. Decreases in Itch protein levels were associated with a reciprocal accumulation of its proapoptotic substrate, TAp73 (p73), and induction of p53 up-regulated modulator of apoptosis (PUMA) mRNA and protein. This event was accompanied by mitochondrial dysfunction, processing of caspase-9, and apoptosis of CLL cells. Ectopic expression of miR106b in CLL cells demonstrated that Itch was a direct target of miR106b such that miR106b-induced decreases in Itch resulted in an accumulation of p73. Thus, our results identify a novel regulatory mechanism wherein microRNA regulate cell survival by mediating the posttranscriptional down-regulation of an ubiquitin ligase, leading to the induction of a proapoptotic regulator in malignant cells. Silencing of miRNA expression in CLL may selectively suppress proapoptotic pathways, providing such tumors with a survival advantage. Consequently, chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096009      PMCID: PMC2670791          DOI: 10.1182/blood-2008-09-178707

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  Genome-wide map of nucleosome acetylation and methylation in yeast.

Authors:  Dmitry K Pokholok; Christopher T Harbison; Stuart Levine; Megan Cole; Nancy M Hannett; Tong Ihn Lee; George W Bell; Kimberly Walker; P Alex Rolfe; Elizabeth Herbolsheimer; Julia Zeitlinger; Fran Lewitter; David K Gifford; Richard A Young
Journal:  Cell       Date:  2005-08-26       Impact factor: 41.582

3.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Authors:  Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

Review 4.  p73, a sophisticated p53 family member in the cancer world.

Authors:  Toshinori Ozaki; Akira Nakagawara
Journal:  Cancer Sci       Date:  2005-11       Impact factor: 6.716

5.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Authors:  H Döhner; K Fischer; M Bentz; K Hansen; A Benner; G Cabot; D Diehl; R Schlenk; J Coy; S Stilgenbauer
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

6.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

Authors:  M MacFarlane; S Inoue; S L Kohlhaas; A Majid; N Harper; D B J Kennedy; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2005-07       Impact factor: 15.828

7.  The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage.

Authors:  Sabrina Strano; Olimpia Monti; Natalia Pediconi; Alessia Baccarini; Giulia Fontemaggi; Eleonora Lapi; Fiamma Mantovani; Alexander Damalas; Gennaro Citro; Ada Sacchi; Giannino Del Sal; Massimo Levrero; Giovanni Blandino
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

8.  Cloning and characterization of human MCM7 promoter.

Authors:  S Suzuki; A Adachi; A Hiraiwa; M Ohashi; M Ishibashi; T Kiyono
Journal:  Gene       Date:  1998-08-17       Impact factor: 3.688

9.  New antibodies recognizing p73: comparison with commercial antibodies.

Authors:  A Emre Sayan; Andrea Paradisi; Borek Vojtesek; Richard A Knight; Gerry Melino; Eleonora Candi
Journal:  Biochem Biophys Res Commun       Date:  2005-04-29       Impact factor: 3.575

10.  The ubiquitin-protein ligase Itch regulates p73 stability.

Authors:  Mario Rossi; Vincenzo De Laurenzi; Eliana Munarriz; Douglas R Green; Yun-Cai Liu; Karen H Vousden; Gianni Cesareni; Gerry Melino
Journal:  EMBO J       Date:  2005-01-27       Impact factor: 11.598

View more
  35 in total

1.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

Review 2.  ITCH as a potential therapeutic target in human cancers.

Authors:  Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2020-03-10       Impact factor: 15.707

3.  Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.

Authors:  Mahmoud Alhosin; Abdulkhaleg Ibrahim; Abdelaziz Boukhari; Tanveer Sharif; Jean-Pierre Gies; Cyril Auger; Valérie B Schini-Kerth
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

4.  p53 downregulates Down syndrome-associated DYRK1A through miR-1246.

Authors:  Yu Zhang; Jun-Ming Liao; Shelya X Zeng; Hua Lu
Journal:  EMBO Rep       Date:  2011-06-03       Impact factor: 8.807

Review 5.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

6.  HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Authors:  Tsung-Huei Lai; Brett Ewald; Alma Zecevic; Chaomei Liu; Melanie Sulda; Dimitrios Papaioannou; Ramiro Garzon; James S Blachly; William Plunkett; Deepa Sampath
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

Review 7.  Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Authors:  Rong-Li Zheng; Yu-Jie Jiang; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

8.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

9.  MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.

Authors:  Manuela Ferracin; Barbara Zagatti; Lara Rizzotto; Francesco Cavazzini; Angelo Veronese; Maria Ciccone; Elena Saccenti; Laura Lupini; Andrea Grilli; Cristiano De Angeli; Massimo Negrini; Antonio Cuneo
Journal:  Mol Cancer       Date:  2010-05-26       Impact factor: 27.401

10.  miR-17-92 cluster: ups and downs in cancer and aging.

Authors:  Johannes Grillari; Matthias Hackl; Regina Grillari-Voglauer
Journal:  Biogerontology       Date:  2010-05-01       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.